Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310126 | 0.88 | CCR1 (0.38) | CCR1CCR5CCR8MAPTMEN1 | |
| SCHEMBL4309068 | 0.80 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL4309243 | 0.79 | CCR1 (0.50) | CCR1CCR5CCR8SMN1; SMN2CYP1A2 | |
| SCHEMBL4309284 | 0.79 | EIF4E (0.36) | CCR1CCR5CCR8MAPTMEN1 | |
| SCHEMBL4304654 | 0.77 | CYP19A1 (0.35) | CCR1CCR5CCR8MAPTMEN1 | |
| SCHEMBL4303003 | 0.76 | CCR1 (0.44) | CCR1CCR5CCR8MAPTCYP1A2 | |
| SCHEMBL4309065 | 0.76 | KCNH2 (0.47) | CCR1CCR5CCR8MAPTKMT2A | |
| SCHEMBL4308839 | 0.75 | EIF4E (0.34) | MAPTCYP1A2ALDH1A1 | |
| SCHEMBL2538923 | 0.73 | CCR1 (0.63) | CCR1CCR5CCR8SMN1; SMN2CYP1A2 | |
| SCHEMBL827247 | 0.73 | CCR1 (0.48) | CCR1CCR5CCR8MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | MT-CO2, MT-CO1, SOD1 | CCR1 2729/4885CCR5 2351/4885CCR8 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.